JP2014524920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524920A5 JP2014524920A5 JP2014520521A JP2014520521A JP2014524920A5 JP 2014524920 A5 JP2014524920 A5 JP 2014524920A5 JP 2014520521 A JP2014520521 A JP 2014520521A JP 2014520521 A JP2014520521 A JP 2014520521A JP 2014524920 A5 JP2014524920 A5 JP 2014524920A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- polymorph
- formula
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 238000000634 powder X-ray diffraction Methods 0.000 claims 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 23
- 239000013078 crystal Substances 0.000 claims 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 12
- 239000012046 mixed solvent Substances 0.000 claims 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 9
- 235000019439 ethyl acetate Nutrition 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 6
- 230000008018 melting Effects 0.000 claims 6
- 238000002844 melting Methods 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 3
- 229940011051 isopropyl acetate Drugs 0.000 claims 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- 238000010992 reflux Methods 0.000 claims 3
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- -1 Synthesis of Compound 5 Compound Chemical class 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 229940125782 compound 2 Drugs 0.000 claims 2
- 229940126214 compound 3 Drugs 0.000 claims 2
- 229940125898 compound 5 Drugs 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- 239000011261 inert gas Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 230000002269 spontaneous effect Effects 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 claims 1
- LVSVSUCJJFSWSY-UHFFFAOYSA-N C(C)(=O)OC.[N+](#[C-])CC(=O)O Chemical compound C(C)(=O)OC.[N+](#[C-])CC(=O)O LVSVSUCJJFSWSY-UHFFFAOYSA-N 0.000 claims 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 229960000583 acetic acid Drugs 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- 239000012297 crystallization seed Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000004821 distillation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012362 glacial acetic acid Substances 0.000 claims 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 239000012074 organic phase Substances 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000002390 rotary evaporation Methods 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 208000037905 systemic hypertension Diseases 0.000 claims 1
- WXRGABKACDFXMG-UHFFFAOYSA-N trimethylborane Chemical compound CB(C)C WXRGABKACDFXMG-UHFFFAOYSA-N 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- WPFRVDGFFDXCKM-UHFFFAOYSA-N COC(C(NC(c1cc(Oc2ccccc2)ccc11)=O)=C1O)=O Chemical compound COC(C(NC(c1cc(Oc2ccccc2)ccc11)=O)=C1O)=O WPFRVDGFFDXCKM-UHFFFAOYSA-N 0.000 description 1
- VCOCTEDFDWIIBJ-UHFFFAOYSA-N COC(c1c(-c2cc(Oc3ccccc3)ccc2C(O)=O)[o]cn1)=O Chemical compound COC(c1c(-c2cc(Oc3ccccc3)ccc2C(O)=O)[o]cn1)=O VCOCTEDFDWIIBJ-UHFFFAOYSA-N 0.000 description 1
- UMMWEAOVAUETLR-UHFFFAOYSA-N COC(c1nc(Cl)c(cc(cc2)Oc3ccccc3)c2c1O)=O Chemical compound COC(c1nc(Cl)c(cc(cc2)Oc3ccccc3)c2c1O)=O UMMWEAOVAUETLR-UHFFFAOYSA-N 0.000 description 1
- YOZBGTLTNGAVFU-UHFFFAOYSA-N Cc(nc1C(NCC(O)=O)=O)c(cc(cc2)Oc3ccccc3)c2c1O Chemical compound Cc(nc1C(NCC(O)=O)=O)c(cc(cc2)Oc3ccccc3)c2c1O YOZBGTLTNGAVFU-UHFFFAOYSA-N 0.000 description 1
- QSGJZCCNTOCDRI-UHFFFAOYSA-N Cc(nc1C(NCC(OC)=O)=O)c(cc(cc2)Oc3ccccc3)c2c1O Chemical compound Cc(nc1C(NCC(OC)=O)=O)c(cc(cc2)Oc3ccccc3)c2c1O QSGJZCCNTOCDRI-UHFFFAOYSA-N 0.000 description 1
- RQLQUCXIJNHBDY-UHFFFAOYSA-N Cc(nc1C(O)=O)c(cc(cc2)Oc3ccccc3)c2c1O Chemical compound Cc(nc1C(O)=O)c(cc(cc2)Oc3ccccc3)c2c1O RQLQUCXIJNHBDY-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1cc(Oc2cc3c(C)nc(C(OC)=O)c(*)c3cc2)ccc1 Chemical compound Cc1cc(Oc2cc3c(C)nc(C(OC)=O)c(*)c3cc2)ccc1 0.000 description 1
- CRZSSXUMRNESCC-UHFFFAOYSA-N N#Cc(c(C#N)c1)ccc1Oc1ccccc1 Chemical compound N#Cc(c(C#N)c1)ccc1Oc1ccccc1 CRZSSXUMRNESCC-UHFFFAOYSA-N 0.000 description 1
- NTZMSBAAHBICLE-UHFFFAOYSA-N N#Cc(c(C#N)c1)ccc1[N+]([O-])=O Chemical compound N#Cc(c(C#N)c1)ccc1[N+]([O-])=O NTZMSBAAHBICLE-UHFFFAOYSA-N 0.000 description 1
- HDQBHDKNRKRCNH-UHFFFAOYSA-N O=C(c(c1c2)ccc2Oc2ccccc2)OC1=O Chemical compound O=C(c(c1c2)ccc2Oc2ccccc2)OC1=O HDQBHDKNRKRCNH-UHFFFAOYSA-N 0.000 description 1
- FKDITAXSGNKBOZ-UHFFFAOYSA-N OC(c(c(C(O)=O)c1)ccc1Oc1ccccc1)=O Chemical compound OC(c(c(C(O)=O)c1)ccc1Oc1ccccc1)=O FKDITAXSGNKBOZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110207175.6 | 2011-07-22 | ||
| CN201110207175 | 2011-07-22 | ||
| CN201110209657.5 | 2011-07-25 | ||
| CN201110209657 | 2011-07-25 | ||
| CN201110211297.2 | 2011-07-26 | ||
| CN201110211297 | 2011-07-26 | ||
| PCT/CN2012/079058 WO2013013609A1 (en) | 2011-07-22 | 2012-07-23 | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524920A JP2014524920A (ja) | 2014-09-25 |
| JP2014524920A5 true JP2014524920A5 (enExample) | 2015-09-10 |
| JP6099644B2 JP6099644B2 (ja) | 2017-03-22 |
Family
ID=47600518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520521A Expired - Fee Related JP6099644B2 (ja) | 2011-07-22 | 2012-07-23 | プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9206134B2 (enExample) |
| EP (1) | EP2734504B1 (enExample) |
| JP (1) | JP6099644B2 (enExample) |
| KR (1) | KR102029951B1 (enExample) |
| CN (1) | CN104024227B8 (enExample) |
| AU (1) | AU2012289429B2 (enExample) |
| CA (1) | CA2842730C (enExample) |
| ES (1) | ES2606631T3 (enExample) |
| IL (1) | IL230580B (enExample) |
| WO (1) | WO2013013609A1 (enExample) |
| ZA (1) | ZA201401310B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| CN103435546B (zh) | 2012-07-16 | 2016-08-10 | 菲布罗根有限公司 | 制备异喹啉化合物的方法 |
| PL2872488T3 (pl) * | 2012-07-16 | 2019-01-31 | Fibrogen, Inc. | Postacie krystaliczne inhibitora hydroksylazy prolilowej |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| IL296484B2 (en) | 2013-06-06 | 2025-03-01 | Fibrogen Inc | Pharmaceutical formulations of HIF hydroxylase inhibitor |
| HRP20240319T1 (hr) | 2013-06-13 | 2024-05-24 | Akebia Therapeutics, Inc. | Pripravci i postupci za liječenje anemije |
| SG10202012791TA (en) * | 2013-11-15 | 2021-01-28 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| CN103694172A (zh) * | 2013-12-26 | 2014-04-02 | 辽宁亿灵科创生物医药科技有限公司 | 含氮杂芳基化合物的衍生物 |
| HK1247201A1 (zh) | 2015-01-23 | 2018-09-21 | 阿克比治疗有限公司 | 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途 |
| CN106146490B (zh) * | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途 |
| SI3277270T1 (sl) | 2015-04-01 | 2022-04-29 | Akebia Therapeutics, Inc. | Sestavki in postopki za zdravljenje anemije |
| CN104910113B (zh) * | 2015-05-21 | 2017-05-10 | 中国科学院宁波材料技术与工程研究所 | 一种羟基苯酐的制备方法 |
| CN104892509B (zh) * | 2015-06-04 | 2018-03-09 | 苏州明锐医药科技有限公司 | 诺得司他的制备方法 |
| CN108367017A (zh) | 2015-08-13 | 2018-08-03 | 索马根尼科斯公司 | 用于伤口愈合的短小发夹rna与微rna的组合物以及方法 |
| CN105130888A (zh) * | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| CN106916105A (zh) * | 2015-12-28 | 2017-07-04 | 徐州万邦金桥制药有限公司 | 一种纯化可博美的方法 |
| CN106187888A (zh) * | 2016-07-18 | 2016-12-07 | 江苏德源药业股份有限公司 | Fg‑4592单晶及其制备方法 |
| CZ2016627A3 (cs) | 2016-10-07 | 2018-04-18 | Zentiva, K.S. | Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu |
| CN107954931B (zh) * | 2016-10-17 | 2021-06-22 | 上海医药集团青岛国风药业股份有限公司 | 一种诺得司他的制备方法 |
| CN108017583B (zh) * | 2016-11-01 | 2021-04-06 | 徐州万邦金桥制药有限公司 | 一种可博美的制备方法 |
| CN111511371A (zh) * | 2017-08-11 | 2020-08-07 | 雷迪博士实验室有限公司 | 罗沙司他的多晶型物和共晶 |
| ES2898878T3 (es) * | 2017-09-04 | 2022-03-09 | Sandoz Ag | Cocristal de un inhibidor de la prolil·hidroxilasa de HIF disponible por vía oral |
| RU2020121746A (ru) * | 2017-12-01 | 2022-01-04 | Др. Редди'З Лабораториз Лимитед | Способ получения роксадустата и его промежуточных соединений |
| CN109956870A (zh) * | 2017-12-14 | 2019-07-02 | 南京卡文迪许生物工程技术有限公司 | 一种罗沙司他的合成方法及其中间体化合物 |
| CN108059679B (zh) * | 2017-12-27 | 2020-03-24 | 吉林大学 | 一种人源单链抗体及其应用 |
| CN110218184B (zh) * | 2018-03-01 | 2022-09-27 | 广东东阳光药业有限公司 | 诺德司他共晶及其制备方法 |
| CN115246789B (zh) * | 2018-03-16 | 2023-10-17 | 上海医药集团青岛国风药业股份有限公司 | 一种诺得司他的制备方法 |
| CN108424388B (zh) * | 2018-04-19 | 2020-08-21 | 杭州科巢生物科技有限公司 | 一种慢性贫血药物的制备方法 |
| CA3097219A1 (en) | 2018-05-09 | 2019-11-14 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| CN110903242B (zh) * | 2018-09-14 | 2023-05-12 | 四川科伦药物研究院有限公司 | 罗沙司他中间体的制备方法 |
| CN109369525A (zh) * | 2018-12-29 | 2019-02-22 | 安礼特（上海）医药科技有限公司 | 罗沙司它的新晶型及其制备方法 |
| WO2020178847A1 (en) | 2019-03-01 | 2020-09-10 | Mylan Laboratories Limited | Cocrystal of roxadustat and d-proline |
| CN109776415B (zh) * | 2019-03-07 | 2020-11-17 | 福建南方制药股份有限公司 | 一种Roxadustat中间体的制备方法 |
| IL287258B1 (en) | 2019-04-18 | 2025-09-01 | Nikang Therapeutics Inc | Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha |
| CN109956901B (zh) * | 2019-04-25 | 2022-09-06 | 南京正大天晴制药有限公司 | 异喹啉酮类化合物的制备方法 |
| WO2021026307A1 (en) | 2019-08-07 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of roxadustat and intermediates thereof |
| CN112679428A (zh) * | 2019-10-17 | 2021-04-20 | 罗欣药业(上海)有限公司 | 罗沙司他新晶型及其制备方法 |
| WO2021073623A1 (zh) * | 2019-10-18 | 2021-04-22 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN112679429B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN112679431B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN112679430B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| EP4049999A4 (en) * | 2019-10-22 | 2023-04-19 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF A HYPOXIA-INDUCTIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| CN111205224B (zh) * | 2020-04-22 | 2020-08-25 | 南京佰麦生物技术有限公司 | 一种罗沙司他水合物的晶型及其制备方法和应用 |
| CN113801060B (zh) * | 2020-06-13 | 2025-06-27 | 苏州鹏旭医药科技有限公司 | 一种多取代异喹啉化合物的制备方法 |
| US12410140B2 (en) | 2020-06-19 | 2025-09-09 | Jumpcan (Shanghai) Medical Technology Co., Ltd | Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof |
| CN112194624A (zh) * | 2020-11-18 | 2021-01-08 | 江苏豪森药业集团有限公司 | 一种异喹啉类化合物的晶型及其制备方法 |
| CN112500344B (zh) * | 2020-11-18 | 2022-07-01 | 江苏豪森药业集团有限公司 | 罗沙司他晶型及其制备方法 |
| CN115144480B (zh) * | 2021-03-31 | 2023-11-28 | 成都倍特药业股份有限公司 | 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法 |
| CN115724796A (zh) * | 2021-08-26 | 2023-03-03 | 成都苑东生物制药股份有限公司 | 一种罗沙司他新晶型及其制备方法 |
| WO2023095162A1 (en) | 2021-11-26 | 2023-06-01 | Mylan Laboratories Limited | Cocrystal of roxadustat and nicotinamide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5470285A (en) * | 1977-11-14 | 1979-06-05 | Tanabe Seiyaku Co Ltd | Production of 4-hydroxyisocarbostyryl-3-carboxylic analog |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CA2444704C (en) * | 2001-04-23 | 2012-07-10 | University Of Virginia Patent Foundation | Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents |
| CN103145616B (zh) * | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| US7189697B2 (en) | 2004-04-13 | 2007-03-13 | Trustees Of Tufts College | Compositions and uses of a galectin for treatment of dry eye syndrome |
| JP5390184B2 (ja) * | 2005-06-06 | 2014-01-15 | ファイブローゲン、インコーポレーテッド | 貧血の改良された治療方法 |
| US7728130B2 (en) | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
| EP2044028B1 (en) * | 2006-01-27 | 2012-05-16 | Fibrogen, Inc. | Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| JP4311416B2 (ja) | 2006-06-30 | 2009-08-12 | 株式会社日立製作所 | 渦電流探傷法による表面欠陥長さ評価方法 |
| WO2011006355A1 (en) | 2009-07-15 | 2011-01-20 | Beijing Beta Pharma Inc. | Compounds as hypoxia mimetics, and compositions, and uses thereof |
-
2012
- 2012-07-23 ES ES12817360.6T patent/ES2606631T3/es active Active
- 2012-07-23 JP JP2014520521A patent/JP6099644B2/ja not_active Expired - Fee Related
- 2012-07-23 WO PCT/CN2012/079058 patent/WO2013013609A1/en not_active Ceased
- 2012-07-23 EP EP12817360.6A patent/EP2734504B1/en not_active Not-in-force
- 2012-07-23 CN CN201280036322.0A patent/CN104024227B8/zh active Active
- 2012-07-23 US US14/233,902 patent/US9206134B2/en active Active
- 2012-07-23 CA CA2842730A patent/CA2842730C/en active Active
- 2012-07-23 KR KR1020147004452A patent/KR102029951B1/ko not_active Expired - Fee Related
- 2012-07-23 AU AU2012289429A patent/AU2012289429B2/en active Active
-
2014
- 2014-01-22 IL IL230580A patent/IL230580B/en active IP Right Grant
- 2014-02-20 ZA ZA2014/01310A patent/ZA201401310B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524920A5 (enExample) | ||
| JP6799037B2 (ja) | 化学的方法 | |
| JP5535082B2 (ja) | ボセンタン、その多形形態及びその塩の合成方法 | |
| KR102240865B1 (ko) | Pde4 억제제의 제조 방법 | |
| CN102985416B (zh) | 制备凝血酶特异性抑制剂的方法 | |
| US9663550B2 (en) | Method for preparing abiraterone acetate | |
| CN107365275B (zh) | 高纯度的赛乐西帕 | |
| KR102266680B1 (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
| JP2022145951A (ja) | （４ｓ）－４－［４－シアノ－２－（メチルスルホニル）フェニル］－３，６－ジメチル－２－オキソ－１－［３－（トリフルオロメチル）フェニル］－１，２，３，４－テトラヒドロピリミジン－５－カルボニトリルの製造方法 | |
| JP2022526675A (ja) | ２－（３，５－ジクロロフェニル）－６－ベンズオキサゾールカルボン酸１－デオキシ－１－メチルアミノ－ｄ－グルシトールの製造方法 | |
| US20190256522A1 (en) | Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same | |
| JP6904519B2 (ja) | 抗腫瘍薬物ニラパリブの中間体を合成するための製造方法および中間体 | |
| WO2021020998A1 (ru) | Способ получения роксадустата | |
| JP5485138B2 (ja) | エチニルチミジン化合物の精製方法 | |
| JP6230703B2 (ja) | ４−ベンジル−１−フェネチル−ピペラジン−２，６−ジオンの製造方法、並びに、その中間体及び製造方法 | |
| JP5745050B2 (ja) | 新規モンテルカスト４−ハロベンジルアミン塩およびこれを用いたモンテルカストナトリウム塩の製造方法 | |
| JP2012509267A (ja) | （Ｒ）−３−（２，３−ジヒドロキシプロピル）−６−フルオロ−５−（２−フルオロ−４−ヨードフェニルアミノ）−８−メチルピリド［２，３−ｄ］ピリミジン−４，７（３Ｈ，８Ｈ）−ジオン及びその中間体を製造するためのプロセス | |
| JP5357559B2 (ja) | ジメトキシナフタレン骨格を有する化合物及びその製造方法 | |
| JP2012506367A (ja) | 結晶性モンテルカストの塩 | |
| JP2019536746A (ja) | フェニルアラニン類化合物の製造方法 | |
| US20150246869A1 (en) | Process for Preparing Cinacalcet and Pharmaceutically Acceptable Salts Thereof | |
| CN109496215B (zh) | 一种福沙匹坦磷酸酯中间体及其制备方法 | |
| JP6516576B2 (ja) | （３ｒ，４ｓ）‐１‐（４‐フルオロフェニル）‐［３（ｓ）‐ヒドロキシ‐３‐（４‐フルオロフェニル）プロピル］‐［４‐（フェニルメトキシ）フェニル］‐２‐アゼチジノンの製造方法 | |
| JP2014523917A5 (enExample) | ||
| CN110590641B (zh) | 一种3-羟基异吲哚-1-酮系列化合物的绿色制备方法 |